Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population

Autor: Elisabeth Pérez-Ruiz, A. Lozano, S. Vázquez Fernández, Raquel Seijas-Tamayo, Ricard Mesia, Miren Taberna, Juan J. Cruz-Hernández, E. del Barco Morillo, R. González Sarmiento, J.C. Adansa Klain, M. Pastor Borgoñón, Javier Fernández-Mateos
Rok vydání: 2016
Předmět:
Male
0301 basic medicine
Oncology
Cancer Research
medicine.medical_treatment
Cetuximab
medicine.disease_cause
KRAS-LCS6
Antineoplastic Agents
Immunological
0302 clinical medicine
Epidermal growth factor receptor
CCDN1
biology
Head and neck squamous cell carcinoma (HNSCC)
FCGR3A
Middle Aged
ErbB Receptors
Head and Neck Neoplasms
030220 oncology & carcinogenesis
Carcinoma
Squamous Cell
Female
KRAS
Oral Surgery
medicine.drug
medicine.medical_specialty
EGFR
SNP
Single-nucleotide polymorphism
FCGR2A
03 medical and health sciences
Internal medicine
medicine
Humans
Polymorphism
neoplasms
Polymorphism
Genetic
Toxicity
Squamous Cell Carcinoma of Head and Neck
business.industry
Epidermal growth factor receptor (EGFR)
medicine.disease
Head and neck squamous-cell carcinoma
digestive system diseases
Radiation therapy
030104 developmental biology
Spain
biology.protein
business
Zdroj: Oral Oncology. 63:38-43
ISSN: 1368-8375
Popis: ObjectivesTo examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab.Material and methodsMulticenter, retrospective, observational pilot study which included 110 patients with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages (III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003 and 2013. Genetic analyses for single nucleotide polymorphisms (SNP) in genes EGFR, CCDN1, FCGR2A, FCGR3A and KRAS-LCS6 were performed though available allelic discrimination assay and/or polymerase chain reaction-restriction fragment length polymorphism methods.ResultsAcneiform rash was observed in 55.5% of patients, dry skin in 45.5% and pruritus in 20.9%. A significant association with dry skin and global cetuximab-related toxicity was observed for the KRAS-LCS6 (rs61764370) variant (p
Databáze: OpenAIRE
Externí odkaz: